Company Profile

Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company's next-generation HbS polymerization inhibitor. The Company is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.

Employees

457

Sector

Biotechnology & Medical Research

More about the company

22-10-06	BioPharma Credit Receives $175 Million From Global Blood Therapeutics Investment	MT
22-10-06	Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P Global BMI Index	CI
22-10-06	Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P TMI Index	CI
22-10-06	Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P Biotechnology Select Industry Index	CI
22-10-05	Global Blood Therapeutics, Inc. Announces Cessation of Ted W. Love as Chief Executive Officer	CI
22-10-05	Global Blood Therapeutics, Inc. Announces Executive Changes	CI
22-10-05	Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index	CI
22-10-04	Pfizer Inc. completed the acquisition of Global Blood Therapeutics, Inc. from a group of shareholders.	CI
22-10-04	Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Biotechnology Index	CI
22-09-07	Insider Sell: Global Blood Therapeutics	MT
22-08-19	Insider Sell: Global Blood Therapeutics	MT
22-08-12	Biotech stocks pin bounce back hopes on M&A boost	RE
22-08-09	Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal	MT

22-08-09	Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal	MT
22-08-09	SVB Securities Downgrades Global Blood Therapeutics to Market Perform from Outperform, Sets $68.50 Price Target	MT
22-08-09	Wells Fargo Downgrades Global Blood Therapeutics to Equalweight From Overweight, Adjusts Price Target to $68.50 From $66	MT
22-08-09	Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral From Overweight, Adjusts Price Target to $68.50 From $75	MT
22-08-09	William Blair Downgrades Global Blood Therapeutics to Market Perform From Outperform	MT

22-10-27	Pfizer Completes $5.4 Billion Acquisition Of Sickle Cell Disease Drug Innovator	AQ
22-10-05	GLOBAL BLOOD THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Regi (form 8-K)	AQ
22-09-30	GLOBAL BLOOD THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	AQ
22-09-23	GLOBAL BLOOD THERAPEUTICS, INC. : Other Events (form 8-K)	AQ
22-09-15	GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022	AQ

22-10-05	Pfizer : finalise l'acquisition de Global Blood Therapeutics
22-08-08	Pfizer compra Global Blood Therapeutics en un acuerdo de 5.400 millones de dólares
22-08-08	Résumé des principales informations économiques du lundi 8 août 2022
22-08-08	Pfizer acquista Global Blood Therapeutics per 5,4 mld dollari
22-08-08	LATE BRIEFING - Unternehmen und Märkte -2-

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/5/22	Jeffrey Farrow	Issuer sale	Chief Financial Officer	448,218	0.6643%
10/5/22	Deval Patrick	Issuer sale	Director	29,709	0.0440%
10/5/22	Dawn Svoronos	Issuer sale	Director	62,923	0.0933%

Global Blood Therapeutics, Inc. Stock

Stocks

GBT

US37890U1088

Biotechnology & Medical Research

Latest news: Global Blood Therapeutics, Inc.

Analysts' recommendations: Global Blood Therapeutics, Inc.

Press Releases: Global Blood Therapeutics, Inc.

News in other languages: Global Blood Therapeutics, Inc.

Quotes and Performance

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLOBAL BLOOD THERAPEUTICS, INC.	+0.01%	+0.56%	-	-	4.62B
WUXI APPTEC CO., LTD.	+0.88%	+1.18%	+40.64%	+74.91%	64.69B
ARGENX SE	-0.26%	+6.91%	+9.79%	+77.36%	54.78B
LONZA GROUP AG	+0.47%	+3.52%	+9.71%	+100.95%	53.49B
IQVIA HOLDINGS INC.	-1.35%	+3.77%	+26.90%	+49.61%	45.98B
BEONE MEDICINES AG	-1.52%	+0.46%	+17.89%	+124.21%	42.94B
REVOLUTION MEDICINES, INC.	-1.19%	+1.47%	+218.71%	+828.28%	40.08B
CELLTRION, INC.	-2.26%	-2.06%	+15.38%	+45.14%	33.52B
WUXI BIOLOGICS (CAYMAN) INC.	+0.22%	-4.77%	+26.59%	+0.55%	23.97B
GENMAB A/S	+12.10%	+16.60%	+58.50%	+46.15%	23.67B
Average	+0.71%	+2.22%	+47.12%	+149.68%	42.57B
Weighted average by Cap.	+0.28%	+2.59%	+44.36%	+151.16%